Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Nikole J, Byrne"'
Autor:
Nikole J. Byrne, BSc, Nirmal Parajuli, PhD, Jody L. Levasseur, BSc, Jamie Boisvenue, BTech, Donna L. Beker, Grant Masson, BSc, Paul W.M. Fedak, MD, PhD, Subodh Verma, MD, PhD, Jason R.B. Dyck, PhD
Publikováno v:
JACC: Basic to Translational Science, Vol 2, Iss 4, Pp 347-354 (2017)
This study sought to determine whether the sodium/glucose cotransporter 2 (SGLT2) inhibitor empagliflozin improved heart failure (HF) outcomes in nondiabetic mice. The EMPA-REG OUTCOME (Empagliflozin, Cardiovascular Outcome Event Trial in Type 2 Diab
Externí odkaz:
https://doaj.org/article/b8f761721afe4ce8a10d25385c71df66
Publikováno v:
Circ Res
As a muscular pump that contracts incessantly throughout life, the heart must constantly generate cellular energy to support contractile function and fuel ionic pumps to maintain electrical homeostasis. Thus, mitochondrial metabolism of multiple meta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88f33b38f48683d63bf37f977885e9f9
https://doi.org/10.1161/circresaha.122.320334
https://doi.org/10.1161/circresaha.122.320334
Autor:
Maria Areli Lorenzana-Carrillo, Keshav Gopal, Nikole J. Byrne, Saymon Tejay, Bruno Saleme, Subhash K. Das, Yongneng Zhang, Alois Haromy, Farah Eaton, Michelle Mendiola Pla, Dawn E. Bowles, Jason R. B. Dyck, John R. Ussher, Evangelos D. Michelakis, Gopinath Sutendra
Publikováno v:
Science translational medicine. 14(669)
Pyruvate kinase M2 (PKM2) is a glycolytic enzyme that translocates to the nucleus to regulate transcription factors in different tissues or pathologic states. Although studied extensively in cancer, its biological role in the heart remains unresolved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebd40f68d314ccbfdad52c934a617c5c
https://pubmed.ncbi.nlm.nih.gov/36322626
https://pubmed.ncbi.nlm.nih.gov/36322626
Autor:
Jason R.B. Dyck, John M. Seubert, Wentong Long, Peter E. Light, Taylor Palechuk, Chloe Schneider, Amy J. Barr, Nikole J. Byrne, Jyoti Singh, Khaled Barakat, Ahmed M. Darwesh, Koenraad Philippaert, Subha Kalyaanamoorthy, Mohammad Fatehi, Jordan Wong, Shubham Soni, Zaid H. Maayah
Publikováno v:
Circulation
Supplemental Digital Content is available in the text.
Background: SGLT2 (sodium/glucose cotransporter 2) inhibitors exert robust cardioprotective effects against heart failure in patients with diabetes, and there is intense interest to identify
Background: SGLT2 (sodium/glucose cotransporter 2) inhibitors exert robust cardioprotective effects against heart failure in patients with diabetes, and there is intense interest to identify
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb817f508a14ba9b2fdf22327046d47
http://europepmc.org/articles/PMC8154177
http://europepmc.org/articles/PMC8154177
Publikováno v:
Free Radic Biol Med
Even in the absence of coronary artery disease and hypertension, diabetes mellitus (DM) may increase the risk for heart failure development. This risk evolves from functional and structural alterations induced by diabetes in the heart, a cardiac enti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acc52997f9e9296442e921466b64ca76
https://doi.org/10.1016/j.freeradbiomed.2021.03.046
https://doi.org/10.1016/j.freeradbiomed.2021.03.046
Autor:
Nikole J. Byrne, Constantin N. Witt, Christoph Koentges, Katharina Pfeil, Thomas Pusdrowski, Johannes Gollmer, Ivan Vosko, Christoph Bode, Andreas Zirlik, Heiko Bugger
Publikováno v:
Journal of Molecular and Cellular Cardiology. 173:67
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::953064ce1b0b4b62a7a98c2fa34f61d2
https://doi.org/10.1016/j.yjmcc.2022.08.135
https://doi.org/10.1016/j.yjmcc.2022.08.135
Autor:
Aleksandre, Tarkhnishvili, Christoph, Koentges, Katharina, Pfeil, Johannes, Gollmer, Nikole J, Byrne, Ivan, Vosko, Julia, Lueg, Laura, Vogelbacher, Stephan, Birkle, Sibai, Tang, Timothy, Bon-Nawul Mwinyella, Michael M, Hoffmann, Katja E, Odening, Nathaly Anto, Michel, Dennis, Wolf, Peter, Stachon, Ingo, Hilgendorf, Markus, Wallner, Senka, Ljubojevic-Holzer, Dirk, von Lewinski, Peter, Rainer, Simon, Sedej, Harald, Sourij, Christoph, Bode, Andreas, Zirlik, Heiko, Bugger
Publikováno v:
Journal of lipid and atherosclerosis. 11(2)
Impaired cardiac efficiency is a hallmark of diabetic cardiomyopathy in models of type 2 diabetes. Adiponectin receptor 1 (AdipoR1) deficiency impairs cardiac efficiency in non-diabetic mice, suggesting that hypoadiponectinemia in type 2 diabetes may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a4fda0e17466bd3787910f4a5bda5b40
https://pubmed.ncbi.nlm.nih.gov/35656151
https://pubmed.ncbi.nlm.nih.gov/35656151
Autor:
Dyonne Y. Vos, Jody Levasseur, Jonathan D. Schertzer, John M. Seubert, Mourad Ferdaoussi, John R. Ussher, Zaid H. Maayah, Mya A. Schmidt, Abrar S. Alam, Nikole J. Byrne, Jason R.B. Dyck, Shingo Takahara, Ahmed M. Darwesh, Rami Al Batran, Donna L. Beker, Shubham Soni
Publikováno v:
Circulation. Heart failure. 13(6)
Background: Previous studies have shown beneficial effects of acute infusion of the primary ketone body, β-hydroxybutyrate, in heart failure (HF). However, whether chronic elevations in circulating ketones are beneficial remains unknown. Methods: To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa40224f415ab4c13de3d893fccce130
https://pubmed.ncbi.nlm.nih.gov/32493060
https://pubmed.ncbi.nlm.nih.gov/32493060
Autor:
Martin E. Young, Ahmed M. Darwesh, Zaid H. Maayah, Gary Sweeney, Nikole J. Byrne, Subodh Verma, Jason R.B. Dyck, Nirmal Parajuli, Shingo Takahara, Mourad Ferdaoussi, John M. Seubert, Ayman O.S. El-Kadi, Branko Braam, Nobutoshi Matsumura, Dyonne Y. Vos, Peter E. Light, Jody Levasseur, James Won Suk Jahng
Publikováno v:
Circulation: Heart Failure. 13
Background: Although empagliflozin was shown to profoundly reduce cardiovascular events in diabetic patients and blunt the decline in cardiac function in nondiabetic mice with established heart failure (HF), the mechanism of action remains unknown. M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6e818f38ef452308327e8ce72879c1c
https://doi.org/10.1161/circheartfailure.119.006277
https://doi.org/10.1161/circheartfailure.119.006277
Autor:
Grant Masson, Nirmal Parajuli, Donna L. Beker, Subodh Verma, Jason R.B. Dyck, Jamie Boisvenue, Nikole J. Byrne, Jody Levasseur, Paul W.M. Fedak
Publikováno v:
JACC: Basic to Translational Science, Vol 2, Iss 4, Pp 347-354 (2017)
JACC: Basic to Translational Science
JACC: Basic to Translational Science
Visual Abstract
Highlights • Although empagliflozin markedly reduces heart failure and cardiovascular-related deaths in diabetic patients, whether empagliflozin improves cardiac outcomes in the absence of diabetes is unknown. • Nondiabetic m
Highlights • Although empagliflozin markedly reduces heart failure and cardiovascular-related deaths in diabetic patients, whether empagliflozin improves cardiac outcomes in the absence of diabetes is unknown. • Nondiabetic m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4751d155b68f8527d032991caaa42452
http://www.sciencedirect.com/science/article/pii/S2452302X17301481
http://www.sciencedirect.com/science/article/pii/S2452302X17301481